General
Preferred name
DAPRODUSTAT
Synonyms
GSK1278863 ()
Daprodustat (GSK1278863) ()
GSK-1278863 ()
P&D ID
PD050025
CAS
960539-70-2
Tags
available
drug
Approved by
PMDA
FDA
First approval
2020
Drug Status
investigational
approved
Drug indication
Diabetic foot ulcer
Autism spectrum disorder
Anaemia
Max Phase
Phase 3
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Daprodustat is a compound which inhibits hypoxia inducible factor prolyl hydroxylase (HIF-PH) activity. HIF-PH inhibitors are being investigated as novel therapies for anemia, especially anemia caused by chronic kindney disease (CKD). It is hoped that HIF-PH inhibitors will provide a more effective alternative to the use of erythropoetin replacement therapy plus iron supplementation in CKD patients (GtoPdb)
Compound Sets
13
AdooQ Bioactive Compound Library
A12671
Cayman Chemical Bioactives
19915
ChEMBL Drugs
CHEMBL3544988
DrugBank
DB11682
DrugBank Approved Drugs
DB11682
DrugCentral
5421
DrugCentral Approved Drugs
5421
DrugMAP
DMRNGD2
Guide to Pharmacology
8455
MedChem Express Bioactive Compound Library
HY-17608
ReFrame library
Selleckchem Bioactive Compound Library
daprodustat
TargetMol Bioactive Compound Library
T3197
External IDs
19
Properties
(calculated by RDKit )
Molecular Weight
393.19
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
0
cLogP
1.26
TPSA
124.09
Fraction CSP3
0.74
Chiral centers
0.0
Largest ring
6.0
QED
0.68
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
Angiogenesis
Chromatin/Epigenetic
Metabolic Enzyme/Protease
Target
HIF-PH
HIF/HIF Prolyl-Hydroxylase
HIF
Source data